Panlong Pharmaceutical announced that on August 26, 2026, the company reviewed and approved the share repurchase plan. It plans to use 10 million yuan to 20 million yuan of its own capital to repurchase shares through centralized bidding for employee stock ownership plans or equity incentives. The repurchase period is within 12 months from the date of review and approval. Due to the 2026 semi-annual equity distribution, the maximum repurchase price was adjusted from 35.92 yuan/share to 35.82 yuan/share starting September 16, 2026. As of October 30, 2026, the company had repurchased a total of 26,5075 shares, accounting for 0.1939% of the total share capital. The highest transaction price was 20.29 yuan/share, and the lowest transaction price was 19.3 yuan/share, with a total payment amount of 5.347 million yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.